Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results;Estudio global de adherencia a los tratamientos inmunomoduladores en pacientes con esclerosis múltiple remitente recidivante: Resultados a 2 años

Neurologia

Volumn 25, Issue 7, 2010, Pages 435-442

  Arroyo, E ^a   Grau, C ^a   Ramo, C ^b   Parra, J ^a   Sanchez Solino O ^a  

^a Medical Department   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Adherence; Chronic diseases; Disease modifying therapies; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG COST; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SPAIN;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT COMPLIANCE; PEPTIDES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 77957315350     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2010.01.009     Document Type: Article

References (10)

1. Adherence to Long-Term Therapies. Organización Mundial de la Salud; 2003.
2. Tremlett H.L., Ogel J. Interrupted therapy: Stopping and switching of the ß-interferons prescribed for MS. Neurology. 2003, 61:551-554.
3. Río J., Porcel J., Téllez N., Sánchez-Betancourt A., Tintoré M., Arévalo M.J., et al. Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005, 11:306-309.
4. Taus C., Taffi R., Morelli M., Fié A., Angeleri V.A., Sgolastra M., et al. Adherence to IFNB therapy in MS: An Italian Clinical Setting. Mult Scler. 2001, 7(Suppl 1):S65.
5. Devonshire V., Lapierre Y., MacDonell R., Ramo C., Patti F., Fontoura P., et al. The Global Adherence Project: A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis. Mult Scler. 2006, 12(Suppl 1):S82.
6. Frohman E., Phillips T., Kokel K., Van Pelt J., O'Leary S., Gross S., et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist. 2002, 8:227-236.
7. Treadaway K.D., Brannon K.D., Morrison A., Remington G.M., Olek M., Racke M.K., et al. Factors that influence adherence with disease-modifying therapy in multiple sclerosis. Neurology. 2006, 66(Suppl 2):A30.
8. Holland N., Wiesel P., Cavallo P., Edwards C., Halper J., Kalb R., et al. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehabilitation Nursing. 2001, 26:172-176.
9. Holland N., Wiesel P., Cavallo P., Edwards C., Halper J., Kalb R., et al. Adherence to disease-modifying therapy in multiple sclerosis: Part II. Rehabilitation Nursing. 2001, 26:221-226.
10. Fiore A.P., Fragoso Y.D. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months. Arq Neuropsiquiatr. 2005, 63:738-740.